Fig 5. Binding free energy and its components of each mutant-inhibitor or mutant-partner system.

(a) to (c), The energies for the systems that each involves a mutant and a dimerization partner (ErbB-2, IGF-1R or c-Met). (d) and (e), The energies for those systems concerning a mutant and an inhibitor (gefitinib or erlotinib). (f) The total binding free energies extracted from parts a to e, with the mutation types shown. (g) The statistical results of the mutation types among our NSCLC patients.